Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice.
Although the current trend is to use monotherapy in the treatment of epilepsy, combination therapy is still employed in patients who have failed to respond to monotherapy. There is little clinical or experimental documentation of evidence against or in favor of anticonvulsant combination therapy. In this context, anticonvulsant and neurotoxic pharmacodynamic interactions between phenytoin (PHT) and valproate (VPA) were assessed in an experimental model in mice. All results were expressed in terms of brain drug concentrations for eliminating any pharmacokinetic interaction from the analysis. Both the median neurotoxic and the median anticonvulsant brain concentrations were determined for each drug used alone and for the combination. The interaction for the combination of PHT and VPA was shown to be supraadditive for the anticonvulsant activity, indicating an antiepileptic potentiation, whereas neurotoxicity was simply additive. These results suggest a potential benefit in terms of overall efficacy versus toxicity for the combination of PHT and VPA, as compared with PHT or VPA used alone.
Chez
M G
MG
Department of Neurology, Cleveland Clinic Foundation, Ohio.
Bourgeois
B F
BF
Pippenger
C E
CE
Knowles
W D
WD
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001927:Brain Diseases / Q000139:chemically induced*; D004347:Drug Interactions; D004357:Drug Synergism; D004597:Electroshock; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D051379:Mice; D010672:Phenytoin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D014635:Valproic Acid / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity
D014635:Valproic Acid; D010672:Phenytoin